Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Juni 2026 09:15 ET | Quelle: OPTIMI HEALTH CORP.

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

VANCOUVER, British Columbia, June 10, 2026 (GLOBE NEWSWIRE) -- via IBN – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical...
08. Juni 2026 08:00 ET | Quelle: OPTIMI HEALTH CORP.

Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development

Recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access Ibogaine is under investigation to treat PTSD,...
02. Juni 2026 07:30 ET | Quelle: OPTIMI HEALTH CORP.

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Optimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United...